• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » An Answer for Psychotic Depression

An Answer for Psychotic Depression

February 10, 2020
Randall Moore, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Randall Moore, MD. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Flint AJ et al, JAMA 2019;322(7):622–631


TYPE OF STUDY: Randomized, placebo-controlled trial


Psychotic features in depression indicate a more severe form of the disease, with a higher risk of hospitalization and double the rate of disability compared with non-psychotic depression. A combination of an antipsychotic and an antidepressant is the mainstay of treatment, but how long to continue the antipsychotic is an unanswered question.


This study enrolled patients 18–85 years of age with severe major depression and at least one delusion; hallucinations were optional. Dementia and unstable medical illness were part of the exclusion criteria, so the patients may not have been as ill as some whom we see in clinical practice. Average age was 55 years.


Researchers first treated 269 patients with open-label olanzapine and sertraline. Next, 162 patients who achieved remission or near-remission entered an open-label 8-week stabilization phase. Of the 147 who remained well after the stabilization, 126 were randomized to continue on olanzapine or have the antipsychotic replaced with a placebo for 36 weeks. The design was double blind, and the antipsychotic taper took place over 4 weeks. All patients remained on sertraline throughout the trial.


The primary outcome was risk of relapse, which included relapses into depression or psychosis as well as psychiatric hospitalization or suicidality. 55% of sertraline-placebo patients relapsed, compared to 20% of sertraline-olanzapine patients. The number needed to treat (NNT) to keep patients well with continued antipsychotic therapy was 2.8.


The majority of the relapses (79%) occurred within the first 20 weeks of the 36-week randomization phase. In a letter to the editor, Klaus Munkholm and colleagues argued that these relapses may have been a withdrawal phenomenon. The authors of the study countered that their criteria for relapse shared little in common with known symptoms of antipsychotic withdrawal.


Weight gain was the main side effect of continued olanzapine. The placebo group lost weight while the olanzapine group continued to gain, with a difference of 9 pounds between them at the end of the study. Falls were also greater in the olanzapine-continuation group (31% vs 18%).


TCPR’S TAKE
When a patient recovers from psychotic depression on an antidepressant and antipsychotic, we should continue both medications for at least 2 months as long as the medication is reasonably tolerable. After 6 months of remission (28 weeks), we might consider a slow taper of the antipsychotic, weighing the severity of the episode, side effects, and the patient’s preferences.

General Psychiatry
KEYWORDS antidepressants antipsychotics deprescribing depression depressive_disorder olanzapine pharmacology pharmacology-tips psychosis psychotic-depression research research-update tardive-dyskinesia
Randall Moore, MD.

Pharmacology for GAD: Complex Choices

More from this author
www.thecarlatreport.com
Issue Date: February 10, 2020
SUBSCRIBE NOW
Table Of Contents
Highlights From This Issue
An Answer for Psychotic Depression
Nuedexta in Agitated Dementia
Inflammatory Biomarkers in Depression
How to Use Pramipexole
Polypharmacy in Schizophrenia
CME Post-Test - Inflammation and Depression, TCPR, February 2020
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto11543850.jpg
    General Psychiatry

    Elvis, Adderall, and a Broken Heart - Part 1

    A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.